Seeking Alpha

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic ...

BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s ...
Seeking Alpha

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant ...

Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB) (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the ...
Nasdaq

INmune Bio's INKmune Receives Veteran Participation In Prostate Cancer Trial

(RTTNews) - INmune Bio, Inc. (INMB), a clinical-stage biotechnology company focused on immunotherapy treatments, announced Tuesday the expansion of its ongoing Phase I/II trial to include veterans ...
Business Wire

Nanostics and Protean BioDiagnostics Partner to Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the United States

CDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer. Florida-based Protean BioDiagnostics will now offer the validated CDX ...
NBC4 Columbus

Deep Bio & Techcyte Partner to Integrate AI-Powered Prostate Diagnostics & Frozen Section on Techcyte Fusion® Platform

OREM, UT, UNITED STATES, August 26, 2025 /EINPresswire.com/ -- Deep Bio, a global leader in AI-powered cancer diagnostics, today announced a strategic partnership ...
KXAN

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer Webinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- ...
Business Wire

Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men

Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact ...
BioTechniques

Targeting prostate cancer’s Achilles’ heel

Scientists have identified two enzymes that help prostate cancer cells grow, survive and resist treatment, paving the way for new and more effective treatments. An international team has uncovered two ...
BioWorld

RNA panel detects and differentiates prostate cancer from benign prostate hyperplasia

Prostate cancer is still one of the main causes of cancer death among men; while prostate-specific antigen (PSA) testing is done for screening, there are recommendations against its use due to its ...